Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. by Lin, Y et al.
Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in
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BACKGROUND: Amplification of aurora kinase A (AK-A) overrides the mitotic spindle assembly checkpoint, inducing resistance to
taxanes. RNA interference targeting AK-A in human pancreatic cancer cell lines enhanced taxane chemosensitivity. In this study, a
novel AK-A inhibitor, CYC3, was investigated in pancreatic cancer cell lines, in combination with paclitaxel.
METHODS: Western blot, flow cytometry and immunostaining were used to investigate the specificity of CYC3. Sulforhodamine B
staining, time-lapse microscopy and colony-formation assays were employed to evaluate the cytotoxic effect of CYC3 and paclitaxel.
Human colony-forming unit of granulocyte and macrophage (CFU-GM) cells were used to compare the effect in tumour and normal
tissue.
RESULTS: CYC3 was shown to be a specific AK-A inhibitor. Three nanomolar paclitaxel (growth inhibition 50% (GI50) 3 nM in PANC-1,
5.1 nM in MIA PaCa-2) in combination with 1mM CYC3 (GI50 1.1 mM in MIA PaCa2 and 2mM in PANC-1) was synergistic in inhibiting
pancreatic cell growth and causing mitotic arrest, achieving similar effects to 10-fold higher concentrations of paclitaxel (30 nM). In
CFU-GM cells, the effect of the combination was simply additive, displaying significantly less myelotoxicity compared with high
concentrations of paclitaxel (30 nM; 60–70% vs 100% inhibition).
CONCLUSION: The combination of lower doses of paclitaxel and CYC3 merits further investigation with the potential for an improved
therapeutic index in vivo.
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Aurora kinases (AKs) are a family of serine/threonine kinases that
are important for mitosis. In mammals, there are three members in
this family, AK-A, AK-B and AK-C (Gautschi et al, 2008). Both
AK-A and AK-B are overexpressed in a number of cancers,
including breast, lung, bladder and pancreas (Gautschi et al, 2008).
Given their association with cancer, both AK-A and AK-B have
become targets for cancer therapy (Lok et al, 2010). Various
selective or non-selective inhibitors of AKs have been developed
and tested as potential cancer therapeutics in clinical or preclinical
studies (Cheung et al, 2009; Kitzen et al, 2010). The majority of
these compounds are pan-aurora inhibitors. Those drugs under
evaluation for use in solid tumours that are reported to be specific
for AK-A include ENMD-2076, which also has VEGFR inhibitor
activity. It showed promising anti-tumour activity, especially in
ovarian cancer in a phase I trial (Diamond et al, 2011), but it has
also recently been shown to inhibit AK-B at concentrations that are
cytotoxic (Wang et al, 2010b), so it is not an AK-A-specific
inhibitor in vivo. MK5108 has more than 200-fold selectivity for
AK-A over AK-B and appears to be AK-A-specific in cells and in
xenograft tumours (Shimomura et al, 2010a). MK5108 is being
tested in a phase I trial in advanced solid tumours with and
without docetaxel (Minton et al, 2010). Another AK-A-specific
inhibitor, MLN8054, was discontinued because of benzodiazepine-
like effects (Dees et al, 2010; Macarulla et al, 2010), and has been
replaced by MLN8237 (alisertib; Manfredi et al, 2011b). MLN8237
is now in phase II trials in lung, breast, head and neck, and
gastrointestinal cancers (Sharma et al, 2011). To our knowledge,
no AK-A-specific inhibitor is being investigated in clinical trials in
pancreatic cancer.
Pancreatic ductal adenocarcinoma is a particularly lethal cancer
with a cumulative 5-year survival rate of less than 5% (Warshaw
and Fernandez-del Castillo, 1992). It is resistant to most current
forms of cytotoxic chemotherapy and ionising radiation (Li et al,
2010). Overexpression of AK-A has been shown in pancreatic
cancer cell lines and tissues (Li et al, 2003; Rojanala et al, 2004). Of
relevance to our studies, amplification of AK-A has been reported
to induce resistance to taxanes (Anand et al, 2003). Knockdown of
AK-A by RNA interference in pancreatic cancer cell lines not only
led to growth inhibition, cell cycle arrest and apoptosis (Hata et al,
2005b; Warner et al, 2006), but also enhanced the taxane
chemosensitivity in these cells (Hata et al, 2005b). Therefore, co-
treatment of an AK-A-specific inhibitor with paclitaxel may be an
intriguing drug combination for pancreatic cancer.
Bone marrow (BM) is very sensitive to many anti-proliferative
agents (Negro et al, 2001). A clinical side effect of paclitaxel
treatment is neutropenia, caused by damage to the neutrophil
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progenitor cells in BM (Rowinsky et al, 1993). A concern in
considering combinations of AK inhibitors and taxanes is that in
the phase I clinical trials of several different dual inhibitors for
both AK-A and AK-B, neutropenia is one of the major side effects
observed (Cheung et al, 2009). In pre-clinical studies to assess
potential myelotoxicity, the colony-forming unit of granulocyte
and macrophage (CFU-GM) assay has been optimised and
validated to predict potential drug myelotoxicity in vitro
(Parent-Massin, 2001), but to our knowledge this has not been
used to test AK-A inhibitors.
In this report, an AK-A-specific inhibitor CYC3 from Cyclacel
Ltd has been tested alone and in combination with paclitaxel in
pancreatic cancer cell lines. To distinguish additivity from synergy,
we employed growth inhibition assays (by sulforhodamine B (SRB)
staining) and mathematical modelling to search for real synergistic
combinations. Later, we confirmed the synergy by time-lapse
microscopy and colony-formation assays. In addition, we inves-
tigated the potential myelotoxicity of the synergistic combination
identified using a CFU-GM assay with human BM cells.
MATERIALS AND METHODS
Cell culture
PANC-1 and MIA PaCa-2 (human pancreatic carcinoma) cells
obtained from the European Collection of Cell Cultures (ECACC;
Health Protection Agency, Salisbury, UK) were verified by STR
genotyping and tested negative for mycoplasma. They were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum at 37 1C and 5% CO2.
Paclitaxel (catalogue number 1097) was obtained from Tocris
Bioscience (Bristol, UK). Paclitaxel and CYC3 were dissolved in
dimethylsulphoxide (DMSO) and then diluted in culture medium
to a final concentration of 0.2% DMSO.
Sulforhodamine assay
Cells were seeded in 96-well plates at concentrations of 3000 PANC-1
cells per well or 2000 MIA PaCa-2 cells per well. Twenty-four hours
later, cells were treated with drugs for 72h. Then, cells were fixed with
trichloroacetic acid and stained with SRB (Skehan et al, 1990).
Fluorescence was quantified using an Infinite 200 PRO plate reader
(Tecan, Reading, UK) at a wavelength of 545nm. Drug-treated wells
were compared with solvent control wells, and the concentration of
drug that resulted in 50% of the cell growth of the solvent control was
designated as the GI50 concentration, calculated using Graphpad
PRISM 5 (Graphpad Software, La Jolla, CA, USA). At least three
biological replicates were performed for each assay.
Synergy calculation
Ninety-six-well plates were treated with a dilution series of each
drug in an 8 8 checkerboard pattern of combinations. After SRB
staining to obtain the growth inhibition data, we used software
that we developed to identify synergistic drug combinations
(SynergySurface, www.synergysurface.com; Figure 3). The single
agent inhibition values were used to calculate a drug combination
surface under the assumption of an additive effect. To obtain this
additive surface, different models of additivity can be used (Bliss,
Loewe and the Highest Single Agent). Details of the three models
and their relative advantages can be found in previous publications
(Jonker et al, 2005; Fitzgerald et al, 2006a); we used the Bliss model
in these studies because it assumes independent mechanisms of
action of the two drugs. Regions of synergy are then detected by
comparing obtained data from a combination with the calculated
additive effect. This is done by subtracting the calculated additive
inhibition values from the measured inhibition to obtain the final
difference values. In the final synergy surface, positive values
hence indicate synergy regions, whereas negative difference values
identify antagonistic effects.
Time-lapse microscopy
Cells were seeded in 96-well plates, and 24 h later cells were
exposed to drug and imaged every 3 h by time-lapse microscopy
using an Incucyte (Essen Bioscience, Welwyn Garden City, UK) for
72 h. The cell confluence was calculated using the Incucyte
software (2010A, Rev2).
Cancer cell colony-formation assay
A total of 20 000 cells were seeded in 6-well plates, and 24 h later
cells were exposed to drugs for 72 h, then counted. Equal numbers
of cells (1000, 2500 and 5000) from each sample were then seeded
in 6 cm plates and left to grow for 7 days. After that, cells
were fixed with 70% methanol and stained with 5% Giemsa (Sigma,
Gillingham, UK). Colony numbers were calculated using Image-
QuanTL (GE Healthcare, Little Chalfont, UK).
Immunostaining
A total of 5000 cells were seeded in 8-well chamber slides (Ibidi,
Mu¨nchen, Germany) and treated with drugs 24 h later. After
treatment, cells were fixed with 4% paraformaldehyde in PBS,
permeabilised with 0.3% Triton X-100 in PBS, then stained with
antibodies and counterstained with DAPI. The primary antibodies
were anti-a-tubulin (T5168, Sigma) and anti-p-AK-A (T288; 3079,
Cell Signalling Technologies, Danvers, MA, USA); secondary
antibodies were anti-rabbit IgG Alexa 647 (4414, Cell Signalling
Technologies) and anti-mouse IgG Alexa 488 (4408, Cell Signalling
Technologies). The confocal image was taken using a Leica IR
Laser microscope (Milton Keynes, UK). The image quantification
was done using Icys research imaging cytometer (Compucyte,
Westwood, MA, USA) and analysed as described in http://
www.compucyte.com/cellcycle.htm.
Western blot
For a typical experiment, proteins were extracted from cells using
RIPA buffer (50mM Tris HCl pH 8.0, 150mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS) and equal amounts (measured
using Bradford assay reagent (Biorad, Hemel Hempstead, UK))
were separated by SDS-PAGE using Novex Bris-Tris 4-12% gels
(Invitrogen, Paisley, UK) in MOPs buffer (Invitrogen) and then
transferred to nitrocellulose membrane (Invitrogen). After block-
ing with Odyssey blocking buffer (LI-COR Biosciences, Lincoln,
NE, USA), blots were stained with primary antibodies from
Cell Signalling Technologies: anti-phospho AK-A/B/C (2914),
anti-AK-A (3092S), anti-cleaved PARP (5625S); from Abcam
(Cambridge, UK): anti-b-actin (ab6276), anti-AK-B (ab2254); and
from Millipore (Watford, UK): anti-p-H3 S10 (06-570). Secondary
antibodies from LiCOR Biosciences were IRDye 680- or 800CW-
conjugated goat anti-mouse or anti-rabbit IgGs (926–32210,
926–32211, 926–32220, 926–32221). The blots were imaged and
quantified using the Odyssey Infrared Imaging System (LI-COR
Biosciences). To detect phospho-aurora A in PANC-1 and
MiaPaCa-2 cells, it was necessary to first increase the level of
aurora A expression by arresting the cells in mitosis with
nocodazole, because the level of aurora A was too low in
asynchronous cell populations.
Flow cytometry
In a typical experiment, cells were harvested by 0.05% trypsin,
retaining the culture media containing floating cells. Cells
were fixed with 70% ethanol, stained with propidium iodide
solution (0.1% v/v Triton-X-100, 20 mgml 1 propidium iodide,
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0.2mgml 1 ribonuclease A in PBS) and analysed using a BD
FACSCalibur flow cytometer (Becton Dickinson, Oxford, UK).
Machine configuration details and representative plots are shown
in the Supplementary Methods). The cell cycle distribution of the
samples was determined using FlowJo version 7.6.1 (Tree Star,
Inc., Ashland, OR, USA).
LC-MS/MS analysis of paclitaxel
Cell pellets obtained after washing in PBS were fixed in ice-cold
methanol (70% v/v) by vigorous vortexing, followed by incubation
at  80 1C for 1 h. The suspension was sonicated, and the cell
extract from untreated cells was used to prepare calibration
standards. An aliquot of the cell suspension (200 ml) was added to
200ml of ice-cold acetonitrile (100% v/v) containing paclitaxel-
[2H5] internal standard. After centrifugation, the supernatant was
evaporated to dryness in a speedvac. For media, 25 ml of the
supernatant was processed in the same way as an aliquot of the cell
suspension. The residue was reconstituted in acetonitrile (50% v/v)
and 20 ml was injected into a Dionex-Ultimate 3000 LC with
autosampler using an Acquity UPLC HSS T3 50mm 2.1mm i.d.,
1.8mm column (Waters, Elstree, UK). The mobile phase was (A)
0.1% acetic acid: (acetonitrile : methanol, (1 : 1)) 70 : 30 and (B)
0.1% acetic acid: (acetonitrile : methanol, (1 : 1)) 10 : 90. The
gradient, at a flow rate of 225ml min 1, was 25% B for 0.2min,
increased to 100% over 0.2min and maintained at 100% for
2.8min, decreased to 25% over 0.2min and maintained at 25% for
2.1min to give a total run time of 5.5min. The LC-MS/MS was
performed on an Applied Biosystems Sciex 4000 Q-trap mass
spectrometer (Applied Biosystems, Carlsbad, CA, USA) equipped
with a turbo-ionspray source and data was acquired using Analyst
1.4.2 software (Applied Biosystems). The mass spectrometry
parameters were set essentially as described by Zhang et al
(2011). Quantitation of the internal standard was done by
multiple-reaction monitoring of the transition 881.4–308.1, with
all other parameters identical to those used for paclitaxel.
Colony-forming unit of granulocyte and macrophage assay
frozen
Human BM mononuclear cells and methylcellulose-based culture
medium (MethoCult H4025 optimum without EPO) were purchased
from Stem Cell Technologies (Grenoble, France). The cells were
counted and suspended in MethoCult medium with or without drugs,
and then 2 104 cells were plated in 35mm petri dishes and cultured
for 14 days as described in the manufacturer’s manual, catalogue
number 28404. Colonies (aggregates with more than 30 cells) were
counted manually using a Nikon TS100 microscope (Nikon, Surrey,
UK); IC50 and IC90 were calculated using Graphpad PRISM 5.
Kinase assays
The IC50 values for purified proteins were determined as
previously described (Wang et al, 2010a). The IC50 values were
determined using XLfit software (IDBS, Surrey, UK). Apparent
inhibition constants (Ki) were calculated from IC50 values and the
appropriate Km (ATP) values for each kinase using the method of
Cheng and Prusoff (1973). Recombinant human AK-A and AK-B
were purchased from Upstate Discovery (Dundee, UK). Aurora A
kinase assays were performed using a 25-ml reaction volume
(25mM b-glycerophosphate, 20m Tris/HCl pH 7.5, 5mkm EGTA,
1mM DTT, 1mM Na3VO4, 10 mg kemptide (peptide substrate) and
recombinant AK-A diluted in 20mM Tris/HCl pH 8, containing
0.5mgml 1 BSA, 2.5% glycerol and 0.006% Brij-35. Reactions
were started by the addition of 5 ml Mg/ATP mix (15mM MgCl2 and
100mM ATP, with 18.5 kBq g-32P-ATP per well) and incubated at
30 1C for 30min before terminating by the addition of 25ml 75mM
H3PO4. Aurora B kinase assays were performed as for aurora A,
except that before use aurora B was activated in a separate reaction
at 30 1C for 60min with inner centromeres protein (Upstate,
Dundee, UK; Sessa et al, 2005). The conversion of IC50 to Ki values
was as follows:
Enzyme IC50 (lM) Km (ATP) Conversion factor
a Ki (lM)
Aurora A 0.033 22 5.55 0.006
Aurora B 0.317 94 2.06 0.154
aConversion factor¼ 1þ (Km ATP/reaction mixture (ATP)). Reaction mixture
(ATP)¼ 100 mM.
M30 ELISA
Cells (106) were seeded in 10 cm plates. After drug treatment, the
culture media were collected and floating cells were removed by
centrifugation. Cleaved cytokeratin 18 induced by apoptosis was
measured and quantified by M30 Apoptosense ELISA (PEVIVA
AB, via Enzo Life Sciences (Exeter, UK) Ltd) according the
manufacturer’s manual.
RESULTS
CYC3 is an AK-A-specific inhibitor
CYC3 is a novel small-molecule inhibitor of AK-A. The inhibitor is
a pyrimido-diazepine analogue (International Patent Number: WO
2009/040556 A1), which has high selectivity for AK-A in vitro.
CYC3 inhibits AK-A at least 25-fold more potently than AK-B
(Table 1) and has limited activity against a panel of 65 additional
protein kinases (Supplementary Table S1). To evaluate the CYC3
effect in pancreatic cancer cells, we first investigated the ability of
CYC3 to inhibit AK-A autophosphorylation on the T288 site
(p-AK-A T288) in cells, which is a marker for AK-A kinase activity.
In both MIA PaCa-2 and PANC-1 cells, CYC3 suppressed p-AK-A
T288 in a dose-dependent manner (Figures 1A and B). In flow
cytometry analysis, CYC3 induced the accumulation of G2/M cells
in a dose-dependent manner (Figure 1C). There was no observa-
tion of significant populations of cells with 8 N DNA content, which
could have indicated endoreduplication, a sign of AK-B inhibition.
In confocal microscopy experiments to investigate the effect of
CYC3 in a single-cell manner, the p-AK-A T288 localised at the
centrosomes as reported (Gautschi et al, 2008) and disappeared
with CYC3 incubation (Figure 1D). Analysis of the cell cycle profile
of the immunostained CYC3-treated cells using iCys (which can
distinguish between cells in G2 and in M phase) revealed an
Table 1 Structure and in vitro kinase selectivity of CYC3
Pyrimido-diazepine core structure Kinase Ki (lM)
N
H
O
N
N
N
N
R2
R3
R1
R4
R5
R6 R7 Aurora A 0.006
Aurora B 0.154
CDK1/cyclin B 420
CDK2/cyclin E 420
CDK4/cyclin D1 420
CDK7/cyclin H 420
CDK9/cyclin T1 420
PLK1 420
PLK4 4.4
Flt3 5.1
Lck 420
Src 6.8
hAbl 4.3
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Figure 1 CYC3 specifically inhibits aurora kinase A activity in cells. (A, B) Cells were treated with 100nM Nocodazole and DMSO, or indicated concentrations
of CYC3 for 24h before collecting. The protein expression levels were determined by western blot and quantified using ImageQuantTL. (C) Flow cytometry analysis
of the cell cycle profiles of MIA PaCa-2 and PANC-1 cells upon treatment with CYC3 as indicated. (D–F) Cells were treated with DMSO or indicated
concentrations of CYC3 for 24h before subjecting to immunofluorescent detection of p-AK-A T288 (arrows) and DAPI (scale bar¼ 25mm). The fluorescent images
are presented in D. iCys research imaging cytometer was used to quantify the mitotic cells (E), and mitotic cells with a positive staining of p-AK-A T288 (F).
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increase in the mitotic cell population (Figure 1E) and a dramatic
decrease in the proportion of mitotic cells, which were p-AK-A
T288-positive (Figure 1F), consistent with the observed cell cycle
arrest and kinase inhibition (Figures 1A–C).
After confirming that CYC3 functions as an AK-A-specific
inhibitor in cells, the effect of CYC3 on cell survival was
investigated in growth inhibition assays using SRB staining.
CYC3 efficiently inhibited both MIA PaCa-2 and PANC-1 cell
proliferation. The 72-h GI50 was 1.1 mM for MIA PaCa-2 cells and
2 mM for PANC-1 cells (Figure 2A). Next, we used time-lapse
microscopy to compare the effect of CYC3 on cell growth over
time. It is clear that CYC3 slows down the cell growth in both MIA
PaCa-2 (Figure 2B) and PANC-1 (Figure 2C) cells in a dose-
dependent manner, with significant inhibition from 1.5mM CYC3
in both cell lines. In addition, increasing concentrations of CYC3
enhanced apoptosis in both MIA PaCa-2 (Figure 2D) and PANC-1
cells (Figure 2E) as measured by PARP cleavage, which is also
consistent with previous publications about the cellular effects of
AK-A-specific inhibition (Hata et al, 2005b; Warner et al, 2006).
Phosphorylated histone H3 at the serine 10 site (p-H3 S10) is a
marker of mitosis and AK-B activity (Gautschi et al, 2008).
Increasing concentrations of CYC3 enhanced the expression of
p-H3 S10 dramatically in PANC-1 cells (Figure 2E), but not in MIA
PaCa-2 cells (Figure 2D), consistent with the greater increase in
mitotic cells seen in PANC-1 in Figure 1E. Of note, CYC3 does not
decrease p-H3 S10 in either cell line, which confirms that at
concentrations p3 mM; CYC3 does not significantly inhibit AK-B.
The anti-proliferative effect of CYC3 was confirmed in six
additional cell lines from a variety of cancers, with a mean IC50
at 72 h of 2.3±1 mM (Supplementary Table S2).
Synergy between CYC3 and low concentration of paclitaxel
To fully evaluate the combination effects of paclitaxel and CYC3,
8 8 concentration combination experiments were performed in
MIA PaCa-2 cells using SRB assays at 72 h; investigating
concentration ranges of 0.03–30 nM of paclitaxel and 0.25–3 mM of
CYC3. We then used the SynergySurface software to investigate
how both drugs interact to inhibit growth in this data set. This
approach identified that 1-3 nM paclitaxel with 0.25–1.5 mM CYC3
inhibits growth more than expected under an additive effect
assumption. However, there was no such synergy detected at
higher concentrations of either agent (Figure 3A). The Emax
(maximum growth inhibition within the area of synergy) was
89±7% growth inhibition at 1 mM CYC3 (IC37 as single agent)þ 3
nM paclitaxel (IC34 as single agent). In statistical analysis of the
SRB data, the inhibitory effect of the 3 nM paclitaxel and 1 mM CYC3
combination on MIA PaCa-2 cells is significantly different
(Po0.01) from the predicted addictive inhibition (Figure 3B). A
similar synergistic region was found in PANC-1 cells, with Emax
70±16% (1mM CYC3, IC13, and 3 nM paclitaxel, IC49).
To further validate the synergy, time-lapse microscopy was used
to evaluate the effect of the combination on cell growth over time
(Figure 3C). On the basis of the growth curves of cells treated with
either 3 nM paclitaxel or 1 mM CYC3 alone, an expected additive
growth curve of the combination was calculated based on the Bliss
Additivity Model. The experimental inhibition achieved using the
combination suppressed the cell growth more than expected under
the assumption of an additive effect of paclitaxel and CYC3. In
MIA PaCa-2 cells, the cell confluence at 72 h in comparison with
the initial cell confluence is 266±11%, compared with an expected
additive effect of 772% (Figure 3C), whereas in PANC-1 cells it is
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236±2% vs 393% (Supplementary Figure S1A), supporting the
existence of synergy between these two compounds. As a third test
of synergy, a colony-formation assay was also used to evaluate the
effect of the combination on cancer cell clonogenic ability
(Figure 3D). On the basis of the effects of single agents, the Bliss
additivity model was used to calculate the expected additive
combination effect on colony formation. We detected a much
greater inhibition of colony formation using the combination
(3.6±1.4% of control) than expected for using an additive
combination (41.4% of control) in the MIA PaCa-2 (Figure 3D)
and PANC-1 cells (13.2±6.5% of control vs predicted 39.1%,
Supplementary Figure S1B), which further confirms the synergistic
interaction of 3 nM paclitaxel and 1 mM CYC3 for inhibiting cell
proliferation.
Myelotoxicity of the combination treatment using CYC3
and paclitaxel
A key question is if the combination will provide a better
therapeutic window (i.e., lower myelotoxicity) when compared
with the high-concentration single-agent activity of paclitaxel.
The potential myelotoxicity of the combination of 3 nM
paclitaxel and 1 mM CYC3 was compared with that seen with
30 nM paclitaxel, using the CFU-GM assay with human BM cells.
Consistent with other reports (Kurtzberg et al, 2009), paclitaxel
had a very steep dose response in colony inhibition from 3 to
10 nM, suggesting there may be a threshold for paclitaxel toxicity in
these progenitor cells (Figure 4A). In contrast, CYC3 demonstrated
a shallow dose-dependent increase in toxicity (Figure 4B). The
Bliss additivity model was used to calculate an additive combina-
tion effect on CFU-GM colony formation. The experimental colony
inhibitory effect of 3 nM paclitaxel with 1 mM CYC3 combination
(40.3±2.7% of control) was similar to the calculated additive
inhibition (43.9 of control), whereas 30 nM paclitaxel treatment
completely abolished all the colonies (Figure 4C). Thus, the
combination of CYC3 and 3 nM paclitaxel was only additive in
terms of toxicity to CFU-GM, whereas it was synergistic in toxicity
to pancreatic cancer cells.
Mechanism of the synergy
Next, the mechanism underlying the synergy was explored further.
The LC-MS spectrometry was used to investigate the cellular and
media concentration of paclitaxel with or without CYC3 co-
treatment in PANC-1 cells. When CYC3 was present, the cellular
paclitaxel level was not significantly different from that observed
in paclitaxel treatment alone (Figure 5A), suggesting CYC3 does
not enhance the cellular uptake of paclitaxel.
The cell cycle arrest and apoptosis induction effects of the
combination treatments were also investigated. Both 30 nM
paclitaxel and the combination of 3 nM paclitaxel with 1 mM CYC3
caused significant G2/M arrest in PANC-1 cells (Figure 5B), which
is accompanied by an increase in p-H3 S10 phosphorylation
(Figure 5D). Although in MIA PaCa-2 cells the induction of G2/M
cell cycle arrest and p-H3 S10 phosphorylation by the same
combination was less, there was an accompanying increase in the
sub-G1 population, suggestive of apoptosis (Figures 5B and C).
Apoptosis was induced sooner in MIA PaCa-2 cells (24 h) than in
PANC-1 (48 h), as measured by PARP cleavage (Figures 5C and D).
Apoptosis was confirmed by the detection of cleaved cytokeratin in
the medium by M30 ELISA (Figure 5E and F, apparent at 48 h in
MIA PaCa-2 vs 72 h in PANC-1). Thus, MIA PaCa-2 cells respond
to the CYC3/paclitaxel combination with less stable arrest in
mitosis and earlier apoptosis than in Panc-1, but in both cells
the combination induces effective growth inhibition when
measured at 72 h.
DISCUSSION
CYC3 shows a 25-fold differential between the in vitro activities
against purified AK-A (IC50 6 nM) and AK-B (IC50 154 nM). In
comparison, MK-5108 (which was in clinical development) had an
IC50 of 0.064 nM against AK-A and 14.1 nM against AK-B
(Shimomura et al, 2010b), and MLN8237 has an IC50 of 1.2 nM
against AK-A and 396.5 nM against AK-B (Manfredi et al, 2011a).
In this study, we have demonstrated that the AK-A inhibitor CYC3
specifically inhibits AK-A activity in vitro in pancreatic cancer
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cells, arresting cells at mitosis, suppressing cell growth and
inducing apoptosis.
We then investigated the activity of CYC3 in combination with
paclitaxel. Many drug combination assays use the combination-
index isobologram method, which is based on the median effect
principle developed by Chou and Talalay (1984), but this method
tests fixed dose ratios of the two drugs, and we wished to
investigate the full interaction surface across a broad range of
concentrations of both drugs. The method developed by Chou and
Talalay (1984) uses a line-fitting technique, but modern advances
in numerical nonlinear solvers can determine the expected
combined effect for any combination of inhibitor concentrations
(Prichard and Shipman, 1990; Fitzgerald et al, 2006b). We chose to
use a checkerboard design to investigate 8 8 dose combinations
in a 96-well plate format. The relative proliferation associated with
different drug concentrations was determined using the SRB assay
(Vichai and Kirtikara, 2006). We then developed a customed
software, which automatically analyses the resulting combination
data for synergistic effects, applying mathematical models to
compare the predicted effect with the experimental data, using
methods similar to those used by Prichard and Shipman (1990),
and Prichard et al (1991). The mathematical models included in
the software include the two most commonly used models for
calculating the expected dose–response relationships from single-
agent data: the Loewe additivity and Bliss independence. The
Loewe additivity model assumes that two inhibitors act through a
similar mechanism and, therefore, the resulting effect can be
described by different equipotent dose ratios (Chou, 2006). The
Loewe additivity model can describe the trivial situation that both
agents are actually the same drug (Jonker et al, 2005), but to apply
this mathematical method both agents have to show a typical
dose–response relationship as single agents. In contrast, the Bliss
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independence model assumes that both drugs modulate different
mechanisms (Fitzgerald et al, 2006a). The Bliss independence
model can be used on any data set, which describes a combination
effect regardless of the shape of the single-agent dose–response
curves, and this is the model we used in these studies. As the
software is able to automatically analyse raw data output from
plate readers, it allows us to test a large number of plates and
concentration combinations more efficiently than other available
software that requires pre-processing of the derived data
(CompuSyn). This approach generates a 3D surface, which can
be interrogated to identify regions of interaction.
Using the software to compare the experimental data with
additivity predictions identified areas of synergy when CYC3 was
combined with a low concentration of paclitaxel (3 nM).
Our data are consistent with that of Hata et al (2005a) who
showed in MIA PaCa-2 and PANC-1 cells that siRNA knockdown
of AK-A enhanced cytotoxicity by 10 nM paclitaxel. Previous
reports of the interaction between AK-A-specific inhibitors and
taxanes in other cell types appear to be consistent. MK-5108 was
shown to synergise with docetaxel to inhibit HeLa-S3 xenograft
tumour growth (Shimomura et al, 2010b), and VE-465 was
reported to synergise with paclitaxel to induce apoptosis in
paclitaxel-resistant and -sensitive ovarian cancer cells (Scharer
et al, 2008). In contrast, Wysong et al (2009) showed that
inhibition of AK-A by MLN8054 abrogated the mitotic arrest
induced by paclitaxel in colorectal and lung cancer cell lines by
allowing mitotic slippage, because AK-A is required for spindle
assembly checkpoint maintenance. However, these authors did not
report the ultimate cell fate beyond 24 h, so this is not necessarily
contradictory to the synergistic cytotoxicity of the taxane/AK-A
inhibitor combination. Also, the paclitaxel used in their study was
100 nM, much higher than the synergistic 3-nM concentration we
identified in our study. Indeed, in the experiments we report
above, at high concentrations of paclitaxel (30 nM), no synergy was
observed. This highlights the importance of investigating wide
ranges of concentrations of both agents, as described in this paper,
to generate a surface of interaction, which can then be interrogated
using modelling approaches.
By measuring the paclitaxel concentration in cells and in media, it
was shown that CYC3 did not alter the uptake of paclitaxel.
P-glycoprotein (P-gp, Mdr-1) is reported to be involved in drug
resistance to paclitaxel by pumping paclitaxel out of the cells (Ueda
et al, 1987a, b). Our result is consistent with a report in breast cancer
cells showing AK-A inhibition does not influence the expression and
function of P-gp (Li et al, 2011), and suggests that a molecular
mechanism underlies the synergy between paclitaxel and CYC3.
It is likely that the combination of 3 nM paclitaxel and 1 mM CYC3
synergise to induce mitotic arrest and subsequent cell death. This
hypothesis is consistent with the observations in PANC-1 cells, but
the combination-induced mitotic arrest in MIA PaCa-2 cells was
less obvious. However, the combination induced apoptosis sooner
in MIA PaCa-2 than in PANC-1 cells. Therefore, a possible
explanation for this cell line discrepancy may be that MIA PaCa-2
cells are more vulnerable to mitotic stress and cannot tolerate
arrest in mitosis for as long as PANC-1 cells. Indeed MIA PaCa-2
and PANC-1 cells also displayed the same differential response to
mitotic arrest by exposure to higher (30 nM) paclitaxel, and
different cancer cell lines are known to vary in their response to
prolonged exposure to anti-mitotic drugs (Gascoigne and Taylor,
2008). The molecular mechanisms underlying this cell line
difference are not clear. Further investigations are needed, which
may shed light on potential biomarkers for better responses to
CYC3 alone and in combination with paclitaxel.
Having identified the areas of synergy, it was important to assess
whether this might impact on the therapeutic index, when using
combination strategies. Although inhibiting synergistically the
growth and clonogenic ability of the cancer cells, the combination
of 3 nM paclitaxel and 1 mM CYC3 did not display synergistic
toxicity towards CFU-GM human BM cells. Thus, there was a
differential response between pancreatic cancer cells and human
BM cells to the drug combination.
Of note, the combination of 3 nM paclitaxel and 1 mM CYC3
achieved a similar magnitude of cytotoxicity as treatment with
higher (30 nM) paclitaxel as a single agent in the cancer cell lines,
but the combination was significantly less toxic than 30 nM
paclitaxel in CFU-GM cells. These differences may reflect
differences in the molecular action of paclitaxel at different
concentrations; 10 nM paclitaxel has been shown to induce
transient mitotic arrest followed by mitotic slippage in some cell
lines, whereas 30 nM paclitaxel induced longer mitotic arrest
without slippage (Riffell et al, 2009); these differences may be
modulated by CYC3 in a different way in cancer cells with multiple
genetic abnormalities than in normal CFU-GM cells. The mechan-
ism of the difference in response of the cancer and normal cells
warrants further investigation. These data suggest that the
combination of CYC3 and low-dose paclitaxel could be associated
with less myelotoxicity than higher doses of paclitaxel and yet be
equally efficacious. This suggests that clinical trials of AKis with
full-dose taxanes may fail because the taxane dose is too high. We
plan to exploit this opportunity to ‘resurrect’ the AKi approach in
pre-clinical and clinical trials, in combination with paclitaxel,
using more rational, science-led dosing schedules.
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